Innovative polatuzumab vedotin plus R-CHP therapy reshapes treatment of older adult patients with diffuse large B-cell lymphoma.

During a live event, Benjamin Garmezy, MD, discussed combinations regimens used for patients with renal cell carcinoma after ...

CEOs exercise warrants early, signaling bullish confidence ahead of a key Phase 3 trial data release. Read more here.

The FDA has approved Opdivo plus Yervoy for the first-line treatment of MSI-H/dMMR colorectal cancer, supported by the Phase ...

The FDA has approved Opdivo with Yervoy for patients 12 years old and older with MSI-H or dMMR colorectal cancer.

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Savolitinib plus osimertinib may be a chemotherapy-free treatment option for patients with EGFR-mutant, advanced NSCLC with MET overexpression/amplification whose disease has progressed on osimertinib ...

Explore the impact of functional respiratory tests on outcomes in anti-CD19 CAR T-cell therapy, presented at EBMT 2025.

Immune checkpoint (IC) inhibitor drug holidays are safe in patients with metastatic melanoma who achieve an objective ...

The combination of nivolumab with ipilimumab was approved for unresectable or metastatic microsatellite instability-high (MSI ...

The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ...